Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. Eur Urol. 2023;84:191–206.

Article  PubMed  PubMed Central  Google Scholar 

Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Res Rep Urol. 2022;14:339–50.

CAS  PubMed  PubMed Central  Google Scholar 

Kratochwil C, Fendler WP, Eiber M et al. May. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023.

Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24.

Article  PubMed  Google Scholar 

Gosewisch A, Ilhan H, Tattenberg S, et al. 3d monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3d localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Res. 2019;9:76.

Article  PubMed  PubMed Central  Google Scholar 

Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60:517–23.

Article  CAS  PubMed  Google Scholar 

Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys. 2020;7:41.

Article  PubMed  PubMed Central  Google Scholar 

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75–81.

Article  PubMed  Google Scholar 

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030–6.

Article  CAS  PubMed  Google Scholar 

Brosch-Lenz J, Delker A, Völter F, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu J, Seifert R, Karkampouna S, et al. Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study. Eur J Nucl Med Mol Imaging. 2025;52:1649–57.

Article  CAS  PubMed  Google Scholar 

Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2021;18:203–11.

Article  CAS  PubMed  Google Scholar 

Wasserthal J, Meyer M, Breit H-C, Cyriac J, Yang S, Segeroth M. TotalSegmentator: robust segmentation of 104 anatomical structures in CT images. 2022.

Dieudonné A, Terro A, Dumouchel A, et al. Towards fully automatized [177Lu]Lu-PSMA personalized dosimetry based on 360° CZT whole-body SPECT/CT: a proof-of-concept. EJNMMI Phys. 2025;12:25.

Article  PubMed  PubMed Central  Google Scholar 

Terro A, Perret S, Dumouchel A, et al. Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy. Med Phys. 2025;52:e18076.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madsen MT, Menda Y, O’Dorisio TM, O’Dorisio MS. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318–24.

Article  PubMed  PubMed Central  Google Scholar 

Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8:32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seifert R, Herrmann K, Kleesiek J, et al. Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer. J Nucl Med. 2020;61:1786–92.

Article  CAS  PubMed  Google Scholar 

Herrmann K, Rahbar K, Eiber M, et al. Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. J Nucl Med. 2024;65:71–8.

Article  CAS  PubMed  PubMed Central  Google Scholar